Impact of radiotherapy on cardiovascular health of women with breast cancer.


Journal

Journal of medical imaging and radiation oncology
ISSN: 1754-9485
Titre abrégé: J Med Imaging Radiat Oncol
Pays: Australia
ID NLM: 101469340

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 08 03 2018
accepted: 24 10 2018
pubmed: 18 12 2018
medline: 14 8 2019
entrez: 18 12 2018
Statut: ppublish

Résumé

This study aims to examine the impact of radiotherapy on the cardiovascular health of women diagnosed with breast cancer in the Waikato region in New Zealand. Women diagnosed with stage 0-III breast cancer and recorded in the Waikato Breast Cancer Registry were divided into two groups: a radiotherapy group and a no-radiotherapy group. Baseline characteristics and treatments were compared in the two groups. Kaplan-Meier survival analysis was performed to compare cardiovascular morbidity and mortality. Cox Proportional Hazard regression analysis was used to estimate the hazard ratio of radiotherapy on the risk of cardiovascular morbidity and mortality while adjusting for other factors. A total of 3528 women were included in this study, with 2303 in the radiotherapy group and 1225 in the no-radiotherapy group. At 10-year follow-up, 11.7% of women in the radiotherapy group and 19.4% in the no-radiotherapy group experienced cardiovascular events. Only 2.3% of patients who received radiotherapy died of cardiovascular disease by 10 years compared to 7.0% in the no-radiotherapy group. After adjusting for clinically significant factors, there was unexplained reduced risk of developing cardiovascular disease in the radiotherapy group compared to the no-radiotherapy group (HR 0.73, 95% CI: 0.59-0.92). No significant difference was found in cardiovascular mortality between the two groups. Radiotherapy appears less likely to be offered to patients at higher risk of cardiovascular disease. No evidence of increased risk of a cardiovascular event was found in the group of women with breast cancer treated with radiotherapy and current regimens appear safe. Traditional cardiovascular risk factors remain the main culprits in this setting. Clinicians should work with patients in managing these risk factors for optimal results.

Identifiants

pubmed: 30556371
doi: 10.1111/1754-9485.12838
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Pagination

250-256

Subventions

Organisme : Health Research Council of New Zealand
Organisme : New Zealand Breast Cancer Foundation
Organisme : Waikato Bay of Plenty Division of the Cancer Society

Informations de copyright

© 2018 The Royal Australian and New Zealand College of Radiologists.

Auteurs

Ross Lawrenson (R)

Waikato Medical Research Centre, The University of Waikato, Hamilton, New Zealand.

Chunhuan Lao (C)

Waikato Medical Research Centre, The University of Waikato, Hamilton, New Zealand.

Ahmed Ali (A)

Waikato District Health Board, Hamilton, New Zealand.

Ian Campbell (I)

School of Medicine, The University of Auckland, Auckland, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH